A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants with Mild to Moderate Alzheimer's Disease.
- O'Brien, Terence (Primary Chief Investigator (PCI))
- Brodtmann, Amy (Primary Chief Investigator (PCI))
Project: Research